Get started
Work

Nimotuzumab Plus Concurrent Chemoradiotherapy for Locally Advanced Cervical Squamous Cell Carcinoma: Updated Follow-up from the Randomized, Phase 3 CC3 Study

Year: 2025
Type: article
DOI: 10.1016/j.ijrobp.2025.06.1255
Authors: J. Wang, P. Jiang, A. Qu, L.C. Wei, L. Zou, X.F. Li, C. Wang, X. Sun, L. Ding, X. Yuan, H. Cheng, D. Wu, R. Cai, R. Yin, J. Zhang, H. Qiu, T. Wang, K. Gao, Y. Zhuo, Y. Zhang
Institutions: Peking University Third Hospital, Air Force Medical University, Dalian Medical University, Second Affiliated Hospital of Dalian Medical University, Peking University Cancer Hospital, Liaoning Cancer Hospital & Institute, Inner Mongolia Medical University, Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine of Hebei Province, Zhengzhou University, Henan Cancer Hospital, Nanfang Hospital, Shanghai Jiao Tong University, Ruijin Hospital, Sichuan University, West China Second University Hospital of Sichuan University, Shanxi Provincial Cancer Hospital, Zhongnan Hospital of Wuhan University, Jilin University, Guangxi Medical University, Tumor Hospital of Guangxi Medical University, Zhangzhou Municipal Hospital of Fujian Province, Third Affiliated Hospital of Harbin Medical University
Language: English
Field: Medicine
Open Access status: bronze
Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Varian Medical Systems, Merck KGaA, BeiGene
OpenAlex ID: W4414558526
FWCI:
Cites:
Cited by:
Related to: 10